

7th Stop TB Coordinating Board meeting

14-15 October 2004, Beijing, China

Draft Decisions/ Actions (CB-STB 04-02)

Objectives

1. Reach consensus on a clear direction to communicate progress towards the 2005 and 2015 Targets;
2. Set priorities for 2005 Stop TB resources and financing mechanisms;
3. Identify mechanisms for closer collaboration with the HIV/AIDS community;
4. Discuss opportunities for engaging Heads of State to stop tuberculosis

Outcomes

- Common understanding on the progress towards the 2005 global targets, and projected situation in 2005;
- Endorsement of the MDG as stop TB targets towards 2015;
- Common understanding on the progress of the Partnership, specifically related to:
 - a) country progress,
 - b) global progress,
 - c) TB/HIV–MDRTB–Advocacy/Communication working groups
 - d) resource and finances
- Adopt the interim financial update of the Stop TB Partnership Secretariat.
- Agreed on need for more advocacy and engaging Heads of States and other decision-makers through upcoming forums, MDG (UN), donor platforms (EU, G8, GFATM), World Bank, etc.

Session - presentations	Decisions	Actions	Document
1. Opening Welcome words from Vice-Minister Wang Longde, China and Jack Chow, WHO			
1.1 Review Minutes/ action-points last CB meeting	1. The report from the last Stop TB Coordinating Board meeting, 22-23 March 2004, New Delhi was adopted		2.04/14
1.2 Election of the Vice Chair of the Board	2. Mr Tariq Farook was elected as the new Vice chair of the Stop TB Coordinating Board for the next two years 3. The Board expressed thanks to professor Omaswa		2.04/15
2. Decisions on strategy regarding 2005 Targets and beyond			
2.1 Progress towards the Millennium Development Goals	1. The Board endorses the MDGs as the Stop TB Targets to be guiding the Global Partnership in planning and implementing Stop TB action towards 2015		2.04/16

2.2 Millennium Development Goals Project: TB working group report	<p>The Board endorses:</p> <ol style="list-style-type: none"> 1. The recommendations of the working group on TB (Working Group report, p9-13) 2. The inclusion of "TB" in MDG 6, thus "combat HIV/AIDS, TB, malaria and other diseases" (overall MDGs report, p35) after extensive discussion amongst Board members 3. Draft General Assembly resolution point 37 "to request a revision of the targets and indicators for monitoring the MDGs to make them consistent with the technical recommendations of the UN Millennium Project Task Forces and other experts, by mid-2006" (overall MDGs report, p31) 4. Development of advocacy strategy by WG on A & C (in collaboration with MDGs Campaign) to push main TB messages a) launch of MDGs report in January 2005, b) UN special summit on MDGs in September 2005 5. Coordination with second Global Plan to Stop TB (2006-2015) (WHA May 2005) 	<ol style="list-style-type: none"> 1. On behalf of the Partnership, send a letter to Kofi Annan stating that MDGs are now the new targets of the Partnership (<i>Secretariat</i>); 2. At upcoming global events related to the MDG (G8, UN, WHO, WEF, etc), a strong Stop TB voice needs to be heard (<i>All CB members</i>) 3. Ensure TB as part of the preparatory briefings and the G8 Summit with presidency UK (<i>Secretariat and DFID</i>) 4. Stop TB Partnership to get a link on the following web: www.first8.org (<i>Secretariat</i>) 	2.04/17
2.3 TB Care for all: Evolution of DOTS strategy	<p>Board supported the presented concept of DOTS evolution with following suggestions:</p> <ol style="list-style-type: none"> 1. Outline further specifics on 'how' 2. Consider the issue of costs, affordability, feasibility of new approaches in countries 3. Assemble supportive evidence accumulated in recent past 4. Develop outreach-strategy within public health system, and reaching out beyond public health providers 	<ol style="list-style-type: none"> 1. Further development of concept addressing evolution of DOTS (<i>DEWG with other WGs</i>) 2. Evidence on public-private mix to be presented to the next CB (<i>DEWG</i>) 	2.04/21
3. Engaging Heads of States			
	<ol style="list-style-type: none"> 1. Importance of engaging heads of States and political influentials at all national levels up to districts, and beyond health. 	- Prepare a plan to engage in global events, including those beyond the health sector (<i>Secretariat</i>)	2.04/18
4. Country progress			
4.1 Intensified Support and Action in Countries (ISAC)	<p>ISAC is a crucial set of complimentary activities that is needed in countries to meet the increasing demand for technical assistance.</p> <ol style="list-style-type: none"> 1. Technical agencies cannot meet the demands from countries 	<ol style="list-style-type: none"> 1. Develop an advocacy and marketing strategy for ISAC (<i>ACWG</i>) 	2.04/1

Stop TB Coordinating Board

	<p>for technical assistance due to shortage of funding.</p> <ol style="list-style-type: none"> In order to ensure the vital continuity of ISAC funded activities, sustainable sources and modalities of funding must be explored including the greater engagement of the GFATM. There is need to develop a better Advocacy & Communications strategy for ISAC in order to gain wider recognition and support. 	<ol style="list-style-type: none"> Ensure that the current funding will be rapidly channeled to countries from Trust Fund (<i>CIDA, WHO, WB, Secretariat</i>) 	
4.2 Global Fund to fight AIDS, TB, Malaria (GFATM)	<p>Proportion of TB among all GFATM successful proposals is stable at 30%, but funds for TB is only 15%.</p> <ol style="list-style-type: none"> Ensuring sustainable support for countries, technical agencies should negotiate with GFATM and other donors their added value for good proposals and most effective use of funds. Publish a framework with 'GFATM application-examples' on the web for learning, after the DEWG. The GFATM's Technical Review Panel (TRP) needs to be informed on new policy and strategies. The DOTS Expansion Working Group estimates that approx. USD. 500,000 is needed to provide TA-support to countries for Round 5 and that around 170k are necessary to hold a preparatory workshop for consultants to countries. 	<ol style="list-style-type: none"> Following Stop TB-GFATM workshop (22-26 Nov'04), the framework and examples of applications will be published for distribution/ web (<i>DEWG</i>) Coordinate briefings for TRP members (<i>Secretariats WGs</i>) Compile and coordinate existing information and studies from partners (USAID; GFATM), related to funding-flow, implementing programs, etc (<i>Secretariat</i>) 	2.04/1a
4.3 TB and Poverty	<ol style="list-style-type: none"> Board states a long-term commitment for the mainstreaming of poverty related issues in TB control activities. The Poverty focus in TB control must be expanded following the current strategy (Network and WHO Guide). 	<p>- Ensure further alignment between WHO and World Bank on the poverty guidelines (<i>WHO, WB, Secretariat</i>)</p>	2.04/2-2b
4.4 National partnerships	<p>National partnerships, created with strong political support, are successful in mobilizing additional resources (both domestic and international).</p> <ol style="list-style-type: none"> There is need to measure the impact of the national partnerships in countries and (sub)regions as to ensure that the returns justify the costs and efforts. Include HIV/AIDS programmes and activities in the formation of a national partnership to stop TB. 	<p>- Measure impact of national partnerships (<i>Secretariat</i>)</p>	2.04/3-3b
4.5 High Level Missions	<p>There is need to improve the structure and the procedures for High Level Missions (HLM) to ensure its optimal strategic benefit for countries and to address decision makers in the global political</p>	<ol style="list-style-type: none"> Establish high level mission sub-committee (<i>HLM Sub committee</i>) 	2.04/4

	<p>area.</p> <ol style="list-style-type: none"> 1. Board established a sub-committee to formulate the process and procedures for a High Level Mission, chaired by Francis Omaswa, with Miake Bilenge, Irene Koek. 2. Board proposes that high level missions focus on the 8 countries with most missing cases, considering that both China and India have been addressed in 2004. 	<ol style="list-style-type: none"> 2. Develop guiding principles and plan of action in consultation with DOTS Expansion WG (<i>Secretariat</i>) 	
5. Global Partnership issues & Planning			
5.1 Second Global Plan to Stop TB	<ol style="list-style-type: none"> 1. Board endorses key features, development of projections to inform planning process, and strategic directions based on the recommendations of the 2nd ad hoc committee on the TB epidemic, and recommends that the Plan should be framed as part of overall progress towards the 2050 goal of eliminating TB as a global public health problem. 2. Board requests each WG to a) Develop plans (2006-2015) in contribution to the global plan, b) Identify a focal point from the WG, c) Identify resource needs for planning 3. Board proposes launch of Global Plan in late 2005 either as a stand-alone event or in conjunction with one of the following events: the Coordinating Board meeting, the proposed heads of state summit on TB, or at the time when the Partnership reports on progress towards the 2005 targets. 4. Board endorses approach of advocacy champions, suggestions: Nelson Mandela, Amartya Sen, Kofi Annan, Bono 5. Board endorses dissemination of Global Plan advocacy messages to key constituencies, including HIV/AIDS 	<ul style="list-style-type: none"> - Planning meeting with the WGs and further coordination of the planning process (<i>Secretariat</i>) 	2.04/10-10a
5.2 Working groups: MDRTB	<ol style="list-style-type: none"> 1. The Board acknowledges GLC is a key priority of the Partnership and plays a pivotal role in the control of MDRTB/ prevention of the emergence of resistance to 2nd line drugs 2. Recognizes financial sustainability of GLC is at stake—donors should be mobilized to ensure the financial sustainability (including already existing funding mechanisms i.e. GFATM): estimated budget (next 3 yrs): 5 million US\$/ operations GLC 3. Recognizes additional funding is required at country level for a) laboratory capacity strengthening, b) purchase of 2nd line drugs, c) human resource development 	<ul style="list-style-type: none"> - Ensure fundraising for GLC as priority and urgent part of the resource mobilization plan, due to lack of finances as of mid 2005 (<i>Board and Secretariat</i>) 	2.04/11-11a

	4. Endorses and supports intensified coordination/ collaboration between DOTS-Plus WG, DOTS Expansion WG and New Diagnostics WG		
5.3 Partners Forum Evaluation	1. The Board confirms that the Forum is an important instrument of the Stop TB Partnership which needs to be meeting once every 3 years around important global issues needing endorsement and advocacy, possibly in conjunction with other global events (such as eg. GFATM Partnership Forum)	1. Conduct an online poll about the future format and date of the Forum (<i>Secretariat</i>) 2. Propose a concept of the next Forum (eg. Constituency engagement, break-out sessions, advocacy regarding outcomes 2005 Targets, etc) (<i>Secretariat</i>)	2.04/12-12a
6. TB/HIV Strategy			
6.1 TB/HIV	The Stop TB Coordinating Board expressed support to 1. Advocate for more rapid acceleration of country level TB/HIV collaborative activities through high-level meetings and encouraging all Stop TB partners to take up TB/HIV issues, 2. Mobilizing and/facilitating the flow of resources from funding agencies to where they are needed at the District level, considering need to strengthen health systems and address absorption capacity constraints 3. Support to the Working Group's country implementation and advocacy efforts.	1. Use health and HIV forums as opportunities for advocacy for TB (<i>donor, multilateral, ACWG</i>) 2. Close collaboration with DFID on preparations G8 Summit (<i>TB/HIV WG, ACWG, DFID, Secretariat</i>) 3. Operational research and monitoring of TB/HIV policies (<i>TB/HIV WG</i>)	2.04/19
6.2 Moving technologies for rapid detection of TB in HIV/AIDS patients	Board encouraged further development as presented.	- Plans and activities to be brought forward (<i>FIND/Diagnostics WG</i>)	
7. Resources & administration			
7.1 Resource mobilization Plan	Board adopted plan with following adjustments and recommendations: 1. Split actions for \$40 million and \$3.7 billion 2. Gather information on domestic spending for TB using National Health Accounts, etc. 3. Revamp resource mobilization directory 4. Strongly endorse need to put more resources behind resource	1. Revise the plan with adjustments and recommendations (<i>Secretariat</i>) 2. Evolve the Resource mobilization Taskforce to an Advisory Group (<i>Taskforce</i>)	2.04/5-5a

Stop TB Coordinating Board

	mobilization, and strengthen secretariat in this regard	3. Be available for specific Stop TB resource mobilisation events/activities (<i>All CB Members</i>)	
7.2 Ethical guidelines	<ol style="list-style-type: none"> 1. Adopt the ethical guidelines as a framework 2. Clarify that guidelines cover cash and in-kind contributions 3. Add a note to specifically state that prior to their acceptance in-kind contributions must be assured to do no harm 4. Establish a review committee–Secretariat has flexibility to call on Review committee as deemed necessary 	- Establish a review committee (<i>Secretariat</i>)	2.04/6-6a
7.3 Trust Fund taskforce	<ol style="list-style-type: none"> 1. Endorse the Operating Principles of the Stop TB Trust Fund at the WB 2. Move ISAC money from the WB Trust Fund to WHO interim TF and allocate it to countries ASAP 3. Transfer GDF money in the WB Trust Fund directly to IAPSO at no additional fee 4. Finalize the definitive Stop TB Trust Fund at WHO and agree an admin fee for it– ideally at no more than 6% 	<ul style="list-style-type: none"> - Negotiating team to be meeting with WHO for permanent Trust fund negotiations, beginning Nov'04 (<i>Negotiating Committee, Secretariat</i>) - Move the ISAC funding currently in the Trust Fund to countries (<i>Secretariat</i>) 	2.04/7-7a
7.4 Poverty Reduction Strategy Papers	<ol style="list-style-type: none"> 1. Develop toolkit–country focused, and ensure coordination with similar efforts in child health, malaria, etc. 2. Bring toolkit effort together with Poverty Network–coordinate action and guideline development 3. Actively 'advocate' Stop TB within the finance platforms (WB), donor platforms (EU, G8), and MDG processes 	- Actively advocate TB within the respective forums (<i>WB, donor platforms–EU, G8, and MDG</i>)	2.04/8
8. Advocacy, Communication, Social Mobilization Working Group			
Rationale, Purpose, Structure and operations	<ol style="list-style-type: none"> 1. Feedback on formation process, structure, key priorities 2. Technical WG chairs need to assign focal points to ACWG 	- Change the TOR, specifically the terms of chair/vice-chair (<i>ACWG Secretariat</i>)	2.04/13-13a
9. Standards for TB drug supply			
	<ol style="list-style-type: none"> 1. The CB approved the need for Global Standards for Drug Supply 2. The patient should expect certain standards when it comes to drug supply. 3. Including these standards into programme reviews and other monitoring missions will help identify and prioritise where 	- Standards need to be a consensus from all the Stop TB partners and a consensus meeting and writing group should be established (<i>GDF Secretariat</i>)	2.04/9

	support is needed		
10. Utilization of Partnership resources			
Financial situation, budget/ plans 2005	The Board adopted the Interim financial report		2.04/20-20a
11. Closing			
11.1 Evaluation process Executive Secretary	After a year in position, the CB is to advise WHO on performance and possible improvement of functioning of the Stop TB Partnership, Executive Secretary.	- Executive committee members to receive feedback by 15Nov'04 and pass them on to WHO (<i>All CB members</i>)	
11.2 Next Board meeting	Next board meeting: - Board agreed on the importance of Board meetings venue linked to a political/ financial mobilisation opportunity and engagement of high-level officers (President, ministers) of host-country or host-agency	- Spring meeting suggested in a) Brussels, linked to EU/EC, b) London, hosted by DFID, c) NY, hosted by GATB (<i>Secretariat to finalize</i>) - Fall meeting Nov'05 in Assisi, Italy hosted by Stop TB Italy	
11.3 Announcements	- Uganda partnership will be formally launched on the 10th of December - GFATM Board meeting taking place in Arusha (15-16 Nov '04)		

**Stop TB Coordinating Board Meeting
Beijing, People's Republic of China
14-15 October 2004**

List of Participants

Chairs Stop TB Working Groups

Working Group on DOTS Expansion

Dr Karam Shah
NTP Manager
National TB Control Program
Ministry of Health
Federal Government
Government TB Centre
Asghar Mall Road
Rawalpindi
Pakistan
Tel: +42 41 4411709
Fax: +42 51 458 2438
Email: tbc@comsatns.net.pk

Working Group on TB and HIV/AIDS

Dr Gijs Elzinga (unable to attend)
Director of Public Health
National Institute of Public Health
and Environmental Protection (RIVM)
Antonie van Leeuwenhoeklaan 9
Postbus 1
Bilthoven 3720 BA
The Netherlands
Tel: + 31 30 274 2345/2340
Fax: + 31 30 274 4406
Email: gijs.elzinga@rivm.nl

Represented by:

Dr Paul Nunn
Coordinator
Tuberculosis, HIV and Drug Resistance
(THD)
World Health Organization (WHO)
20, avenue Appia
Geneva 27 1211
Switzerland
Tel: (41) 22 791 2963
Fax: (41) 22 791 4268
E-mail: nunnp@who.int

**Working Group on DOTS-Plus for
MDR-TB**

Dr Kai Vink (unable to attend)
NTP Manager
Tartu University Clinics
Lung Clinic
Riia 167, 51014 Tartu
Estonia
Tel: +37 27 318 944
Fax: +372 731 8943
E-mail: kai.vink@kliinikum.ee

Represented by:

Dr Kitty Lambregts
STB/THD
World Health Organization (WHO)
20, avenue Appia
Geneva 27 1211
Switzerland
Tel: (41) 22 791 2385
Fax: (41) 22 791 4268
E-mail: lambregtsk@who.int

Stop TB Coordinating Board

Working Group on Vaccines Development

Dr Douglas Young (unable to attend)
Center for Molecular Microbiology
and Infection (CMMI)
Imperial College of Science, Technology and
Medicine, Flowers Building
London SW7 2AZ
United Kingdom
Tel.: +44 207 594 32011
Fax: +44 171 262 6299
E-mail: d.young@ic.ac.uk

Working Group on TB Diagnostics

Dr Giorgio Roscigno
FIND
71 Avenue Louis-Casai
Case postale 93
1216 Cointrin, Genève
Switzerland
Tel: + 41 (22) 710 05 90
Fax: + 41 (22) 710 05 99
Email:
giorgio.rosicigno@finddiagnostics.org

Global Alliance for TB Drug Development

Dr Maria Freire (unable to attend)
CEO, Global Alliance for TB Drug
Development
59 John Street, #800
New York, NY 10038, USA
Tel: 1 212 227 7540, Ext. 222
Fax: 1 212 227 7541 or +32 2 22368
E-mail: maria.freire@tballiance.org

Advocacy, Communication & Social Mobilization Working Group

Dr Joanne Carter, PhD
Interim Chair
Results International
440 First Street, N.W., Suite 450
20001 - Washington, DC
United States of America
Tel: 1.202.783 7100
Fax: 1.202.783 2818
E-mail: Carter@Action.org

Regional Representatives

African Region(Vice-Chair)

Professor Francis Omaswa
Director-General
Health Services
Ministry of Health
P.O. Box 16069
Wandegaya, Kampala
Uganda
Tel: (256) 75 769106
Fax: (256) 41 340 881
E-mail: dghs@infocom.co.ug

American Region (also Chair STAG/WHO)

Dr Roberto Tapia Conyer (unable to attend)
Vice-Minister Subsecretario
Subsecretaria de Salud
Secretaria de Salud de Mexico
Lieja No.7, Colonia Juarez
Mexico D.F.
Tel: 52 55 555 37145 / 52 555 97 145
Fax: 52 52 86 53 55
Email: rtapia@salud.gob.mx

Eastern Meditteranean Region

Mr Tariq Farook
Federal Secretary
Ministry of Health
Government of Pakistan
Islamabad
Pakistan
Tel: +92 51 92 13562
Fax: +92 51 920 1357
email :

European Region

Dr Jaap F. Broekmans (unable to attend)
Director
Royal Netherlands Tuberculosis Association
(KNCV)
P.O.Box 146
The Hague 2501 CC
The Netherlands
Tel: (31) 70 416 7222 / 7245
Fax: (31) 70 358 4004
E-mail: broekmansj@kncvtbc.nl

Southeast Asia Region

Dr Sombat Tanprasertsuk
Director, Bureau of AIDS, TB and STIs
Department of Disease Control
Ministry of Public Health
Tiwanond Rd., Nonthaburi 11000
Thailand
Tel : 66 2 590 32 01
Fax : 66 2 591 84 13
E-mail: sombat@aidsthai.org

Western Pacific Region

Dr Toru Mori
Director
Research Institute of TB (RIT),
Japan Anti-tuberculosis Association,
3-1-24 Matsuyama, Kiyose
Tokyo 204-0022
Japan
Tel: (81 424) 92 4767
Fax: (81 424) 92 4600
E-mail: tmori@jata.or.jp

High-TB-burden Countries**Brazil**

Dr Jarbas Barbosa da Silva Junior
Ministerio de Saude
Secretaria de Vigilancia em Saude
Explanada dos Ministerios, Bloco G, Ed
Sede do
Ministerio da Saude, Sala 105
Brasilia, DF - Brasil
Tel: 5561 315 3777, 315-3706
Fax: 5551 225-5807
E-mail: jarbas.barbosa@saude.gov.br

China

Dr Wang Longde
Vice Minister
Ministry of Health
Beijing 100044
République populaire de Chine
Tel: +8620 68792031
Fax: +8610 687 92024
E-mail: wangld@moh.gov.cn

India

Mr Prasada Rao
Secretary (Health)
Department of Health & Family Welfare
Government of India
Nirman Bhavan, Room A-345
New Delhi 110 011, India
Tel: +91 11 301 8863
Fax: +91 11 301 4252
Email: secyhlth@hub.nic.in

DR Congo

Dr Constantin Miaka Mia Bilenge
Secrétaire Général
Ministère de la Santé
Boulevard du 30 juin n° 4310
Commune de la Gombe B.P. 3040 KIN
Kinshasa I/Gombé
République Démocratique du Congo
Tel: +243 990 4294 / +243 815182257
Fax : 00 243 511 0 37
E-mail: tshimbadi@yahoo.fr

Multi-Lateral Organizations**WHO**

Dr Mario Raviglione
Director, STB Department
HIV/AIDS, Tuberculosis and Malaria
(HTM)
World Health Organization (WHO)
20, avenue Appia
Geneva 27 1211
Switzerland
Tel: (41) 22 791 2663
Fax: (41) 22 791 4886
Email: raviglionem@who.int

Stop TB Coordinating Board

World Bank

Mr Jacques Baudouy
Director
Health, Nutrition and Population (HDNHE)
The World Bank
1818 H Street, NW
Washington, DC 20433
United States of America
Tel: +1 202 473 2525
Fax: +1 202 522 3234
Email: jbaudouy@worldbank.org

UNAIDS

Dr Catherine Hankins, MD MSc FR CPO
Chief Scientific Adviser to UNAIDS and
Associate Director
Strategic Information
Social Mobilization to Information
Department
United Nations Programme on HIV/AIDS
20 avenue Appia, CH 1211
Geneva 27
Switzerland
Tel: +41 22 791 3865
Fax: + 41 22 791 4746
Email: hankinsc@unaids.org

GFATM

Dr Vinand Nantulya
Director
Strategy and Evaluation
The Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM)
Centre Casai
Avenue Louis-Casai, no. 53
1216 - Cointrin, Geneva
Switzerland
Tel: +41 22 791 1712
Fax: +41 22 791 17 01
Email:
vinand.nantulya@theglobalfund.org

NGO's/Technical Agencies

CDC

Dr Kenneth Castro (unable to attend)
Director Division of TB Elimination
Governmental Organization-Technical
Centers for Disease Control & Prevention,
1600 Clifton Road, MSE10, Corporate Square
Boulevard, Bldg 10
Atlanta GA 30329
United States of America
Tel: +1 404 639 8120
Fax: +1 404 639 8604
Email: kgc1@cdc.gov

IUATLD

Dr Nils Billo
Executive Director
International Union Against Lung Diseases
(IUATLD)
68, boulevard St-Michel
Paris 75006
France
Tel: +(33) 1 44 32 03 61 (direct)
Fax: +(33) 1 4329 90 87
Email: NBillo@iuatld.org

**International Federation of Red Cross
and Red Crescent Societies (IFRC)**
Representative of the Asia delegation

People affected by TB

Mr Mark Harrington (unable to attend)
Executive Director
Treatment Action Group (TAG)
611 Broadway, Suite 612
New York, New York 10012
USA
Tel (office): 1 212 253 7922
Fax: (office) 1 212 253 7923
Pers. Tel: 1 212 353 8430
Email: markharrington@aol.com
www.treatmentactiongroup.org
www.aidsinfonyc.org/tag

Financial Donors

CIDA

Dr Ernest R. Loevinsohn (**Board Chair**)
Director General
Food Aid Centre
& Multilateral Policy
Canadian International
Development Agency (CIDA)
200, Promenade du Portage
Hull, Quebec K1A 0G4
Canada
Tel: +(1) 819 997 9492
Fax: +(1) 819 953 5348
Email: ernest_loevinsohn@acdi-cida.gc.ca

Japan—Ministry of Health, Labour and Welfare

Dr Yukio Matsutani (unable to attend)
Assistant Minister for Technical Affairs
Ministry of Health Labour and Welfare
Government of Japan
1-2-2, Kasumigaseki, Chiyoda-ku
Tokyo 100-8916 Japan
Tel: +81 3 3595 2403
Fax: +81 3 3501 2532
E-mail: matsutani-yukio@mhlw.go.jp

Dr Yasuhisa Nakamura
Deputy Director
International Cooperation Division
Ministry of Health, Labour and Welfare
Government of Japan
2-1-1 Kasumigaseki, Chiyoda-ku
9th Floor MHLW
Tokyo, Japan
Phone: +81 3 5253 1111 (ext 7292)
Fax: + 81 3 3501 2532
E-mail : nakamura-yasuhisa@mhlw.go.jp

Netherlands

Mr Harry van Schooten
Health Adviser
Ministry of Foreign Affairs
Department DGIS
Bezuidenhoutseweg 67
PO Box 20061
2500 EB - The Hague
Netherlands
Tel: + 31 70 348 44 67
Fax: + 31 70 348 48 48/31 70 348 53 66
E-mail: harry.schooten@minbuza.nl

USAID

Dr Anne Peterson (unable to attend)
Assistant Administrator for Global Health
USAID
895 Williamsburg Pond Court
Falls Church, VA 22043
United States of America
Tel: +1 202 712 0970
Fax: +1 202 216 3702
E-mail: apeterson@usaid.org

Dr Irene Koek
Chief, Environmental Health
and Infectious Diseases Division
Office of Health and Nutrition
US Agency for International
Development (USAID)
Ronald Reagan Building
G/PHN/HN/EH, 3.07-75M, 3rd Floor,
RRB
20523-3700 - Washington, DC
United States of America
Tel: + 1 202 712 5403
Fax: + 1 202 216 3702
Email: ikoek@usaid.gov

Stop TB Coordinating Board

Foundations

B&M Gates Foundation

Peter M. Small, M.D.
Senior Program Officer, Tuberculosis
Global Health Program
PO Box 23350
Seattle, WA 98102
Tel: + 206.709.3301
Fax: + 206.709.3170
Email: peters@gatesfoundation.org

Corporate Business Sector

Heineken

Dr Stefaan van der Borgh
Corporate Medical Adviser
Heineken International
2de Weteringsplantsoen 21
1017ZD Amsterdam
The Netherlands
Tel. : + 31 651 241 544
Fax.: +31 71 545 77 88
E-mail : s.vanderborgh@Heineken.com

Special Invitees

Dr Jack Chow
Assistant Director-General
HIV/AIDS, Tuberculosis and Malaria
World Health Organization
Avenue Appia 20
CH-1211, Genève 27
Switzerland
Tel: (41) 22 791 38 00
Fax: (41) 22 791 48 96
E-mail: chowj@who.int

Dr Christopher Dye
Coordinator
Tuberculosis Monitoring and Evaluation
Stop TB Department
HIV/AIDS, TB and Malaria
World Health Organization
Avenue Appia 20
CH-1211, Genève 27
Switzerland
Tel: + 41 22 791 38 00
Fax: + 41 22 791 48 96
Email: dyec@who.int

Observers

Dr L.S. Chauhan
Deputy Director General
Health Services
Ministry of Health and Family Welfare
523 C, Nirman Bhavan
1011 - New Delhi, India
Tel: +91 (11) 230 181 26
Fax: +91 112 - 301 8126
Email: ddgtb@tbcindia.org

Dr Olusoji Adeyi
Coordinator
Global Partnerships for Com. Diseases
Human Development Network
The World Bank
1818 H Street NW
20433 - Washington, D.C, USA
Tel: +1202 4736465
Fax: +1202 5223489
E-mail: oadeyi@worldbank.org

Dr Léopold Blanc
Coordinator
TB Strategy and Operations
Stop TB Department
HIV/AIDS, TB and Malaria
World Health Organization
Avenue Appia 20
CH-1211, Geneva 27, Switzerland
Tel: +41 22 791 42 66
Fax: + 41 22 791 42 68
E-mail: blancl@who.int

Stop TB Coordinating Board

Mr Fraser Fowler
Program Manager
Program Against Hunger, Malnutrition and
Disease
Canadian International
Development Agency (CIDA)
200, Promenade du Portage
Hull, Quebec K1A 0G4
Canada
Tel: + 819 953 0488
Fax: + 819 953 5348
E-mail: FRASER_FOWLER@acdi-
cida.gc.ca

Dr William Stewart
Health Adviser
Global Health Partnerships Team
Policy Division
Department for International Development
(DFID)
1, Palace Street
London SW1E 5HE
Tel: +44 (0)20 7023 0765
Fax: +44 (0)20 7023 0428
E-mail: Billy-Stewart@dfid.gov.uk

People's Republic of China - Host country

Dr Xiao Donglou
Deputy Director General
Department of Disease Control
Ministry of Health

Dr Ren Minghui
Deputy Director General
Department of International Cooperation
Ministry of Health

Dr Qi Qingdong
Assistant Director General
Department of International Cooperation
Ministry of Health

Dr Xing Jun
Acting Director
Division of International Organizations
Department of International Cooperation
Ministry of Health

Mr Yang Xiaobao
Program Officer
Division of International Organizations
Department of International Cooperation
Ministry of Health

Mr Liu Haitao
Program Officer
Department of Disease Control
Ministry of Health

Dr Liu Jianjun
Director
Centre for TB Control and Prevention,
China CDC

Dr Jiang Shiwen,
Expert
Centre for TB Control and Prevention,
China CDC

Dr Chen Shiming
Centre for TB Control and Prevention,
China CDC

Dr Yaohongyan
Centre for TB Control and Prevention,
China CDC

WHO-China

Dr Henk Bekedam
WHO Representative
Beijing, China
Tel. : 86 10 6532 7189
Fax : 86 10 6532 2359
Email : who@chn.wpro.who.int

Dr Daniel Chin
Medical officer TB
Beijing, China
Tel: +86-10-65327189, ext 628
Fax: +86 (106) 5322359
Email: chind@chn.wpro.who.int

Stop TB Partnership Secretariat

Dr Marcos Espinal
Executive Secretary
Stop TB Partnership Secretariat
HIV/AIDS, TB and Malaria
World Health Organization
20, avenue Appia
Geneva 27 1211

Switzerland
Tel: (41) 22 791 2708
Fax: (41) 22 791 4886
Email: espinalm@who.int

Mr Anant Vijay
Resource Administrator
Stop TB Partnership Secretariat
Tel: (41) 22 791 1837
Fax: (41) 22 791 4886
Email: vijaya@who.int

Ms Petra Heitkamp
Principal Officer
Stop TB Partnership Secretariat
Tel: (41) 22 791 2879
Fax: (41) 22 791 4886
Email: heitkampp@who.int

Dr Ger Steenberg
Senior Officer
Stop TB Partnership Secretariat
Tel: (41) 22 791 1345
Fax: (41) 22 791 4886
Email: steenbergen@who.int

Mr Michael Luhan
Advocacy & Communications Adviser
Stop TB Partnership Secretariat
Tel: (41) 22 791 1379
Fax: (41) 22 791 4886
Email: luhanm@who.int

Mr Robert Matiru
Technical Officer
Stop TB Partnership Secretariat
Tel: (41) 22 791 3971
Fax: (41) 22 791 4886
Email: matirur@who.int

Dr Peter Evans
Acting GDF Operations Manager
Stop TB Partnership Secretariat
Tel: (41) 22 791 2519
Fax: (41) 22 791 4886
Email: evansp@who.int

Dr Dermot Maher
Scientist
Stop TB Partnership Secretariat
Tel: (41) 22 791 2655
Fax: (41) 22 791 4886
Email: maherd@who.int